Back to top
more

Canopy Growth (CGC)

(Delayed Data from NSDQ)

$6.21 USD

6.21
1,989,892

+0.07 (1.14%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $6.20 -0.01 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Canopy Growth Corporation (CGC) Soars 6.1%: Is Further Upside Left in the Stock?

Canopy Growth Corporation (CGC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Neena Mishra headshot

Should You Invest in Marijuana Stocks & ETFs Now?

CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.

Canopy Growth (CGC) Surges: Stock Moves 6.3% Higher

Canopy Growth (CGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Cannabis Stocks Rise on Hopes of Federal Legalization in US

Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.

The Zacks Analyst Blog Highlights: Canopy Growth, Tilray, Cisco Systems, Twitter and Lyft

The Zacks Analyst Blog Highlights: Canopy Growth, Tilray, Cisco Systems, Twitter and Lyft

Mark Vickery headshot

Pot Stocks Take Markets Higher; Plus Beats for Cisco, Twitter, Lyft

With Tilray (TLRY) +44% and Canopy (CGC) +12% on the day, the Nasdaq and Russell 2000 managed to climb to fresh all-time highs Tuesday.

Canopy Growth Corporation (CGC) Reports Q3 Loss, Lags Revenue Estimates

Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -366.67% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know

Canopy Growth Corporation (CGC) closed at $44.14 in the latest trading session, marking a -1.78% move from the prior day.

Sweta Killa headshot

Cannabis ETFs Spike on Jazz-GW Pharma Deal

Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.

Canopy Growth (CGC) to Report Q3 Earnings: What's in Store?

Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in fiscal third quarter.

Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Cannabis ETF Tops in January: 5 Stocks That Led the Way

Inside the top performing stocks in the top ETF of January.

Canopy Growth Corporation (CGC) Stock Moves -0.64%: What You Should Know

In the latest trading session, Canopy Growth Corporation (CGC) closed at $40.07, marking a -0.64% move from the previous day.

Sanghamitra Saha headshot

Investing Strategies to Follow on Democratic Senate and House

Democratic taking control of both House and Senate, these investing strategies should prosper in the coming days.

The Zacks Analyst Blog Highlights: IIPR, CRON, CGC and STZ

The Zacks Analyst Blog Highlights: IIPR, CRON, CGC and STZ

Nitish Marwah headshot

4 Stocks to Ride the Wave of Cannabis Legalization

Increasing tolerance, financial protection, credit availability, and legal votes have shaped America's hemp industry lately.

Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know

Canopy Growth Corporation (CGC) closed the most recent trading day at $25.54, moving -1.66% from the previous trading session.

Sweta Killa headshot

ETFs to Buy as Tilray-Aphria Merger Creates Cannabis Giant

Investors seeking to take advantage of the merger deal between Tilray and Aphria could invest in any of the cannabis ETFs.

Neena Mishra headshot

Should You Buy Cannabis Stocks & ETFs Now?

CNBC's cannabis expert Tim Seymour discusses the recent developments in the space.

Company News for Nov 10, 2020

Companies In The News Are: MCD, GSK, PRTY, CGC

Should You Buy Canopy Growth (CGC) Ahead of Earnings?

Canopy Growth (CGC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Canopy Growth (CGC) to Report Q2 Earnings: What's in Store?

Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in fiscal second quarter.

Trina Mukherjee headshot

3 Medical Product Stocks Poised to Beat This Earnings Season

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, on the back of several factors.

Neena Mishra headshot

Why Cannabis Stocks & ETFs Are Soaring

Marijuana stocks are rising on hopes of favorable regulatory environment

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in Pharmaceutical segment.